Improving patient outcomes in acute lymphoblastic leukemia at ASH 2015

Improving patient outcomes in acute lymphoblastic leukemia at ASH 2015

VJHemOnc

4 years
324 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ryan Cassaday, MD, from Fred Hutchinson Cancer Research Center, Seattle, WA, discusses clinical data presented on acute lymphoblastic leukemia (ALL) at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition. Highlights include a clinical trial evaluating rituximab, an anti-CD20 monoclonal antibody, added to a chemotherapy backbone; a phase 2 clinical trial of blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen; and early clinical trials evaluating CD19-targeted chimeric antigen receptor T-cell therapy.
Up Next Autoplay